Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • AiMeD wants govt to...

    AiMeD wants govt to mandate Buy in India for devices with 50 percent price benefit for Indian products

    Written by supriya kashyap kashyap Published On 2017-02-16T10:43:26+05:30  |  Updated On 16 Feb 2017 10:43 AM IST
    AiMeD wants govt to mandate Buy in India for devices with 50 percent price benefit for Indian products

    Association of Indian Medical Device Industry (AiMeD) is of the view that since the government health departments are the largest purchaser of medical devices, it should mandate a Buy in India policy. This along with a 50 per cent price benefit if the supplier is an Indian manufacturer would bolster its Make in India programme. Along with this the government needs to look at a rationalisation of taxes to spur growth prospects for the sector.


    India accounts for 800 medical device companies and country has scope to increase this to 7,000 units. Now in order to give a fillip to Make in India programme, the government needs to extend first choice to Indian manufacturers only. This practice is in vogue across the globe. Therefore India should not shy away from this practice, Rajiv Nath, forum coordinator, Association of Indian Medical Device Industry told Pharmabiz.


    It should covert the import costs of medical devices of Rs. 24,000 crore and pump it in for domestic manufacturers. The basic import tariff needs to be 10 per cent for medical devices which garners export revenue of over Rs. 5 crore. The duty on components needs to be 5 per cent from next year and 7.5 per cent thereafter as a ‘Make in India’ enabler. The concessional duty on raw material can be retained at 2.5 per cent for now, for next three years, he added.


    There is need for a separate ministry for pharma and medical devices. As there is a synergy in the sector. But in the case of medical devices, it requires considerable inter-ministerial coordination like electronics, commerce, DBT, DST, consumer affairs and finance. Medical devices is a life saver and therefore the government should take a cue from Japan where four member team comes directly under the Prime Minister Office. This has seen Japan to emerge from nowhere to a leadership status in the medical devices space, he noted.


    From tariff rationalisation to ban on refurbished medical equipment, the government needs to take a closer look. There is no dearth of talent to manufacture medical device. But the issue is that government recognises global regulations and not the ICMED certification. No Indian healthcare provider will buy a device unless it is carries a global certification. “We are pressing the government to amend voluntary compliance backed by 3rd Party ICMED Certification as a compliance option. There is also need to cover high risk devices in 3rd Party Certification as being done for low risk. If the government recognizes more certifying bodies it will see another 100 medical device players engaged in domestic manufacture, he explained.


    The country’s policy for Preferential Market Access and Preferential Pricing must be like the World Bank terms for public healthcare tenders. In addition the MRP labelling needs to be enforced on unit of sale of medical devices.


    The government should not opt for NPPA for medical devices other than case of stents or combination device, having a drug. Instead it should introduce price cap mechanism of 4-5 times which is ex-factory / import landed price in a phased manner or bring in a 1 per cent cess on excise or GST on MRP to act as disincentive for putting exorbitant MRP and to incentivise ethically correct low MRP.


    Ban on refurbished medical equipment, for next 5 years and a Medical Device Export Promotion & Import Substitution Council could address India’s 70 per cent import dependency and 90 per cent on medical electronics, said Nath.

    (AIMED)Association of Indian Medical Device IndustryICMED certificationIndian Medical Associationmedical deviceMr Rajiv NathNPPA
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok